Industry Symposia

Vegas-style games with an educational twist! Meet our medical team and deepen your knowledge of the Oncotype DX Breast Recurrence Score® and Riskguard® tests with informative and competitive games, while partaking in a strolling dinner.

Join us as we explore how tumor-informed molecular residual disease (MRD) analysis has evolved as a valuable tool in the clinic for patients with breast cancer. In this session, we will review the various clinical challenges patients face and how MRD testing is being used to help inform the care pathway in the neoadjuvant, adjuvant and surveillance settings.

Speakers

• Angel Rodriguez, MD
  Medical Oncologist, Medical Director, Natera
• Erica Giblin, MD
  Breast Surgery, Surgical Oncology, Ascension St. Vincent
• Alice Ho, MD
  Radiation Oncology, Duke Cancer Institute

Join our expert faculty for this interactive symposium to explore the role of systemic neoadjuvant therapy and the importance of MDT collaboration in the treatment of HER2-positive early breast cancer. With your participation, questions and interactive polling, our expert panel will navigate the complexities of systemic neoadjuvant therapy and share best practice of how to seamlessly integrate guideline-based care in your practice. Through case study review, our expert faculty will dissect the complex and interlinking roles of each MDT member within clinical practice.

Program Objective

This meeting aims to bring together HCPs to:

• Explore the clinical benefits of systemic neoadjuvant therapy for eligible patients from multidisciplinary perspectives
• Discuss the importance of multidisciplinary team collaboration in optimizing patient outcomes in HER2-positive eBC
• Review case studies that underpin the importance of tailoring treatment to the individual patient

Speakers

• Dr Lee Schwartzberg
  Chief of Medical Oncology and Hematology, Renown Health / William N. Pennington Cancer Institute, Nevada
• Dr Brigid Killelea
  Co-Director of Oncoplastic Breast Surgery Program, Dana-Faber Institute Boston, Massachusetts

This scientific symposium, featuring leading breast cancer surgeons, will explore the use of post-lumpectomy radiofrequency ablation (RFA) as an intraoperative technique to create an additional tumor-free margin around the lumpectomy cavity in breast cancer patients. This approach has the potential to reduce the need for re-excision due to close (incomplete) margins and may offer an alternative for maintaining local control without radiation therapy in appropriate groups.

The symposium will present long-term data demonstrating the efficacy of various techniques including cryo-ablation, IORT, and post-lumpectomy RFA, along with case studies using a new RFA probe specifically designed for use within the lumpectomy cavity.

Moderator

• Sheldon Feldman, MD
  Chief, Division of Breast Surgery & Breast Surgical Oncology Director, Breast Cancer Services Professor of Surgery, Montefiore Einstein

Speakers

• Suzanne Klimberg, MD, PhD, MSHCT, FACS, MAMSE
  Vice Chair, Administration, Division Chief, Surgical Oncology, Clinical Director, Cancer Center and Medical Director, Breast Cancer Service Line, Associate Chief Research Officer Professor, Surgery
• Cem Yilmaz, MD
  Breast Surgeon and Founding Director, Istanbul Oncology Hospital
• Jill Dietz, MD, FACS
  Professor of Surgery, NYU Langone Grossman School of Medicine
  Director of Surgical Quality and Innovation, Perlmutter Cancer Center

Program Objectives

• Recall clinical data on a treatment option for patients with a certain type of TNBC
• Discuss the signs of adverse reactions and monitoring and management considerations with this treatment
• Apply clinical data to a case study of a patient using this treatment option

Speaker

• Anees Chagpar, MD

Program Objectives

• Learn perioperative patient management strategies to help reduce surgical complications​
• Review key clinical evidence and economic data which illustrate the benefits of using negative pressure therapy in challenging patient populations
• Enhance understanding of proper marking techniques and incision design to optimize patient outcomes and minimize surgical site complications ​
• Learn tips and pearls to apply advanced modalities in challenging clinical scenarios ​
• Participate in hands-on cadaveric dissection

Speakers

• Abhishek Chatterjee, MD, MBA
  Chief of the Division of Plastic Surgery
  Division of Surgical Oncology
  Tufts Medical Center
  Boston, MA
• Regina M. Fearmonti, MD
  Fearmonti Plastic Surgery
  Alon Aesthetics Plastic Surgery & Skin
  San Antonio, TX

Experiences, studies and decision-making around management of cavity and radiation considerations for contemporary BCS

Speakers

• Susan K. Boolbol, MD
  NuVance Health
• Shawna Willey, MD
  Inova Schar Cancer Institute
• Jennifer Gass, MD
  Brown, Women & Infants
• Sunny Mitchell, MD
  Montefiore Nyack Medical Center
• Patricia Clark, MD
  Parkview Health

During this symposium, Dr. Jaime Alberty MD, FASC and Dr. Beth DuPree MD, FACS, ADOIM will discuss the latest data and clinical utility of MammaPrint and BluePrint in guiding neoadjuvant treatment and surgical planning decisions. Topics include: risk stratification to identify who benefits from neoadjuvant therapy, the importance of genomic subtyping and pCR rates with BluePrint, and the implications of axillary management with genomic insights from MammaPrint and BluePrint. The session will include case studies and opportunity for Q&A with the speakers.

Program Objective

Understand the insights gained from MammaPrint® and BluePrint® to increase precision in identifying who responds to neoadjuvant treatment and associated pCR rates, the importance of BluePrint genomic subtyping to inform neoadjuvant decisions, and how MP + BP identify patients most likely to achieve nodal downstaging and less invasive axillary staging.

Speakers

• Dr. Jaime Alberty MD, FASC
• Dr. Beth DuPree MD, FACS, ADOIM

EBC Meeting to Educate on the treatment of patients with high-risk EBC. HR+, HER2- EBC: Patient Identification and Tailoring Treatment

Program Objective

• Explain the risk of disease recurrence and how this can guide treatment strategies
• Assess which patients may benefit from the addition of a CDK4/6 inhibitor and formulate individualized treatment plans to optimize patient selection
• Formulate strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors to support treatment adherence and maximize clinical outcomes

Speaker

• Naomi Dempsey, MD
  Breast Medical Oncologist
  Miami Cancer Institute
  Member, Memorial Sloan Kettering Cancer Alliance

Moderator

• Eleftherios (Terry) Mamounas, MD
  Medical Director Breast Program and Research Activities
  AdventHealth Cancer Institute
  Breast Surgical Oncology

Join us at the ASBrS Annual Meeting on Friday, May 2nd, 2025 for Friday Night Live! - an evening dedicated to exploring the latest breakthroughs in breast cancer surgery, with food and drink.

Hosted by Dr. Susan K. Boolbol, System Chief, Breast Surgical Oncology and Breast Program at Nuvance Health, this symposium brings together surgical pioneers to share their experiences of using the new Magseed Pro® localization marker.

The event offers a unique opportunity to witness exclusive new surgical footage, straight out of the OR. See how easy it is to use Magseed Pro alongside the Magtrace® lymphatic tracer, learn about the 96% reduced volume of MRI artifact, and hear firsthand insights from those at the forefront of innovation.

Speakers

• Dr Alastair Thompson (Baylor St Luke’s, Texas) — A foremost expert on the Sentimag® platform and one of the first in the US to perform a Magseed Pro® surgery.
• Dr Rhiana Menen (Mountain State Breast & General Surgery, Idaho) — A prominent user of Magseed® & Magtrace®, discussing the MagTotal technique and her published findings on Sentimag’s health economic value.
• Dr Elizabeth Kraft (Hoag Hospital, California) — A recent adopter of Sentimag®, with fresh insights on why she prefers Magseed Pro® to other seed technologies.
• Miss Rachel O’Connell (The Royal Marsden Hospital, London UK) — With over two years of experience recruiting for the Magseed Pro® European clinical trial, she will share case findings and improvements in patient treatment pathways.

An interactive evening featuring dynamic discussions on the use of Stryker's Breast Portfolio including the utility and benefits of fluorescence imaging in lymphatic mapping and a deep dive into MOLLI, a wire-free, radiation-free lesion localization technology that enhances surgical precision in lumpectomies

Speakers

• Abhishek Chatterjee, MD, MBA, FACS
• Sheldon Feldman, MD
• Anne Peled, MD
• David Weintritt, MD, FACS

• Discuss the pros and cons of surgeon infiltration vs. anesthesia performing regional blocks
• Follow best practices when collaborating with your anesthesia team to optimize the patient experience
• Understand the potential impact of the NOPAIN Act

Speakers

• Jeffrey Gadsden, MD
  Duke University
• Risal Djohan, MD
  Cleveland Clinic

Overview

Silbiotech, Inc. will host a breakfast symposium on managing atypical hyperplasia patients using genomic test, BBDRisk Dx, for personalized clinical decision-making. The test is approved for coverage by Medicare, Medicare Advantage Plans, Medicaid of several States, UnitedHealthCare, BCBS of most States and several other commercial insurance agencies. The clinical study, test development, validation and publications will be presented. Data on several Case Reports will also be presented. Audience will have an opportunity to ask questions.

Topics to Be Discussed

• Breast Cancer Rates among Atypical Hyperplasia Patients
• Genomic Test for Personalized Risk Assessment
• Genomic Information for Informed Management

Speaker

• Indira Poola, PhD
  Lead Scientist for developing BBDRisk Dx Test
  Silbiotech, Inc.

New CPT codes now permit surgeons to bill and be reimbursed for patient navigation services administered by their staff. Discover how XpediteMD's digitally enhanced navigation platform empowers your practice to elevate patient navigation services and reliably capture associated revenues. XpediteMD's platform streamlines these services, ensuring efficient delivery and accurate billing, thereby enhancing both patient care and practice profitability.

Speakers

• Dennis R. Holmes, MD, FACS
  Co-founder and CEO at XpediteMD, Inc.
• Riya Pullicharam, MD, CPI
  Co-founder and CMO at XpediteMD, Inc.
• Artem Petrov
  Head of Product at XpediteMD, Inc.